Skip to main content

FDA Approvals

FDA Approvals
Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions
Read More
FDA Approvals
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Read More
FDA Approvals
Tecartus First CAR T-Cell Therapy FDA Approved for Patients with Mantle-Cell Lymphoma
Read More
FDA Approvals
Imbruvica (Ibrutinib) Receives Expanded Indication, in Combination with Rituximab, as First-Line Treatment for Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Mayzent (Siponimod) Approved for Relapsing Forms of Multiple Sclerosis, Including Active Secondary Progressive Disease
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Pemazyre (Pemigatinib) First Targeted Therapy FDA Approved for Cholangio­carcinoma with FGFR2 Biomarker
Loretta Fala
Read More
FDA Approvals
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
Loretta Fala
Read More
FDA Approvals
Trodelvy (Sacituzumab Govitecan-hziy) a New Targeted Therapy for Patients with Metastatic Triple-Negative Breast Cancer
Loretta Fala
Read More
FDA Approvals
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Loretta Fala
Read More
Page 15 of 53
Results 141 - 150 of 522